Nasus Pharma Ltd has disclosed a significant change in ownership involving its Chief Financial Officer, Sassi Nir. In a recent filing, Nir acquired options to purchase 115,000 ordinary shares of the company. This move is part of a strategy to align executive compensation with the company's performance and growth prospects.

The acquisition of these options is noteworthy as it reflects Nasus Pharma's ongoing commitment to incentivizing its executive team. In a competitive landscape, particularly within the pharmaceutical preparations sector, such strategies are essential for attracting and retaining top talent.

Background

Nasus Pharma Ltd operates in the pharmaceutical preparations industry, classified under SIC code 2834. The company is publicly traded on the NYSE under the ticker symbol NSRX. As an emerging growth company, Nasus Pharma is focused on developing innovative solutions in the healthcare sector.

What the Filing Says

According to the SEC filing dated November 19, 2026, Sassi Nir has been granted options to purchase 115,000 ordinary shares at varying exercise prices. The options are set to vest over a period of thirty-six months, with one-third vesting on November 11, 2027, and the remaining two-thirds in eight equal quarterly installments starting February 11, 2028. The filing noted, "On November 11, 2026, the Issuer granted options to purchase 115,000 ordinary shares... under its 2019 Incentive Option Plan." This plan is designed to motivate executives by tying their compensation to the company's performance.

Impact

This change in ownership may impact various stakeholders, including investors and employees. By granting share options to executives, Nasus Pharma aims to enhance performance and drive shareholder value. Such moves can also influence employee morale and retention, as they create a sense of ownership and alignment with the company's goals.

What's Next

The filing does not say what happens next.